- Home
- NRIX
as 03-28-2025 4:00pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $30.82 | AVG Volume (30 days): | 946.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.90 - $29.56 | Next Earning Date: | 04-09-2025 |
| Revenue: | $54,549,000 | Revenue Growth: | -29.14% |
| Revenue Growth (this year): | 1.77% | Revenue Growth (next year): | 6.62% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| van Houte Hans | NRIX | Chief Financial Officer | Mar 3 '25 | Sell | $14.76 | 5,825 | $84,387.72 | 34,424 | |
| Ring Christine | NRIX | Chief Legal Officer | Jan 31 '25 | Sell | $20.21 | 5,760 | $114,933.87 | 32,638 | |
| van Houte Hans | NRIX | Chief Financial Officer | Jan 30 '25 | Sell | $20.07 | 2,811 | $55,808.69 | 34,424 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Jan 30 '25 | Sell | $20.07 | 3,690 | $73,259.85 | 55,937 | |
| Ring Christine | NRIX | Chief Legal Officer | Jan 30 '25 | Sell | $20.07 | 3,220 | $63,928.87 | 32,638 | |
| Ring Christine | NRIX | Chief Legal Officer | Jan 2 '25 | Sell | $19.50 | 5,760 | $112,294.66 | 32,638 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
MT Newswires
12 days ago
Nurix Therapeutics' Blood Cancer Drug Candidate Gets FDA Orphan Drug Designation
GlobeNewswire
12 days ago
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
GlobeNewswire
15 days ago
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
16 days ago
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
Zacks
16 days ago
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
Zacks
17 days ago
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?
GlobeNewswire
25 days ago
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.